BR112018070249A2 - sistema promotor de u6 modificada para expressão específica de tecido - Google Patents
sistema promotor de u6 modificada para expressão específica de tecidoInfo
- Publication number
- BR112018070249A2 BR112018070249A2 BR112018070249A BR112018070249A BR112018070249A2 BR 112018070249 A2 BR112018070249 A2 BR 112018070249A2 BR 112018070249 A BR112018070249 A BR 112018070249A BR 112018070249 A BR112018070249 A BR 112018070249A BR 112018070249 A2 BR112018070249 A2 BR 112018070249A2
- Authority
- BR
- Brazil
- Prior art keywords
- tissue specific
- promoter system
- specific expression
- expression modified
- mirna
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title abstract 3
- 108091070501 miRNA Proteins 0.000 abstract 5
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H5/00—Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Botany (AREA)
- Developmental Biology & Embryology (AREA)
- Environmental Sciences (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317524P | 2016-04-02 | 2016-04-02 | |
| PCT/US2017/025614 WO2017173411A1 (en) | 2016-04-02 | 2017-03-31 | Modified u6 promoter system for tissue specific expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018070249A2 true BR112018070249A2 (pt) | 2019-01-29 |
Family
ID=59965277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018070249A BR112018070249A2 (pt) | 2016-04-02 | 2017-03-31 | sistema promotor de u6 modificada para expressão específica de tecido |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11345913B2 (enExample) |
| EP (2) | EP4335502A3 (enExample) |
| JP (2) | JP7253379B2 (enExample) |
| KR (1) | KR102453187B1 (enExample) |
| CN (1) | CN109714954A (enExample) |
| AU (1) | AU2017240236C1 (enExample) |
| BR (1) | BR112018070249A2 (enExample) |
| CA (1) | CA3019832C (enExample) |
| IL (1) | IL262056B2 (enExample) |
| MA (1) | MA44528A (enExample) |
| RU (1) | RU2768289C2 (enExample) |
| WO (1) | WO2017173411A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3668997A4 (en) * | 2017-10-02 | 2021-05-19 | Research Institute at Nationwide Children's Hospital | SYSTEM FOR MIRNA DETARGETING FOR TISSUE-SPECIFIC INTERFERENCE |
| CN108823209B (zh) * | 2018-07-18 | 2021-04-09 | 华中农业大学 | 骨骼肌特异性启动子及应用 |
| JP2021533200A (ja) | 2018-08-02 | 2021-12-02 | ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. | 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12492402B2 (en) | 2018-08-22 | 2025-12-09 | Research Institute At Nationwide Children's Hospital | Recombinant virus products and methods for inhibiting expression of dystrophia myotonica protein kinase and/or interfering with a trinucleotide repeat expansion in the 3′ untranslated region of the DMPK gene |
| JP2022516515A (ja) * | 2018-12-31 | 2022-02-28 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | Ｒｎａ標的化ｃｒｉｓｐｒ－ｃａｓ１３ｂを使用するｄｕｘ４ ｒｎａ発現停止 |
| EP4127175A4 (en) * | 2020-04-02 | 2025-01-22 | Mirecule, Inc. | Targeted inhibition using engineered oligonucleotides |
| WO2022056266A2 (en) | 2020-09-11 | 2022-03-17 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use |
| US12275941B2 (en) * | 2021-04-15 | 2025-04-15 | Research Institute At Nationwide Children's Hospital | Products and methods for inhibition of expression of dynamin-1 variants |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| ATE272123T1 (de) | 1993-11-09 | 2004-08-15 | Ohio Med College | Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren |
| EP0733103B1 (en) | 1993-11-09 | 2004-03-03 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| EP0796339A1 (en) | 1994-12-06 | 1997-09-24 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
| JPH11511326A (ja) | 1995-08-30 | 1999-10-05 | ジエンザイム コーポレイション | アデノウィルスおよびａａｖの精製 |
| US6632670B1 (en) | 1995-09-08 | 2003-10-14 | Genzyme Corporation | AAV vectors for gene therapy |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| ATE465267T1 (de) | 1996-09-06 | 2010-05-15 | Univ Pennsylvania | Rekombinante aav zur herstellung eines medikaments für die gentherapie von muskelzellen |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| WO1999011764A2 (en) | 1997-09-05 | 1999-03-11 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| CA2406743A1 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
| AU2002248297A1 (en) | 2001-01-05 | 2002-07-16 | Children's Hospital, Inc. | Aav2 vectors and methods |
| ES2602352T3 (es) | 2001-12-17 | 2017-02-20 | The Trustees Of The University Of Pennsylvania | Secuencias de serotipo 8 de virus adenoasociado (VAA), vectores que las contienen y usos de las mismas |
| EP1838144B1 (en) | 2005-01-07 | 2016-08-31 | Oregon State University | Method to trigger rna interference |
| PT2164967E (pt) | 2007-05-31 | 2015-10-27 | Univ Iowa Res Found | Redução da toxicidade não dirigida do arn de interferência |
| EP2235179B1 (en) | 2007-12-24 | 2017-11-15 | BerGenBio ASA | Methods for creating and identifying functional rna interference elements |
| US9217155B2 (en) * | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| JP2013533847A (ja) * | 2010-04-23 | 2013-08-29 | ユニバーシティ オブ マサチューセッツ | コレステロール関連障害のａａｖベースの治療 |
| US20120225034A1 (en) | 2010-09-02 | 2012-09-06 | Universite De Mons | Agents useful in treating facioscapulohumeral muscular dystrophy |
| WO2012143401A1 (en) | 2011-04-18 | 2012-10-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tissue-specific regulation of transgene expression |
| ES2990023T3 (es) * | 2011-07-25 | 2024-11-28 | Nationwide Childrens Hospital Inc | Productos de virus recombinantes y métodos para inhibición de la expresión de DUX4 |
| WO2013120038A2 (en) * | 2012-02-10 | 2013-08-15 | Regents Of The University Of Minnesota | Morpholino targeting dux4 for treating fshd |
| DE102012007232B4 (de) | 2012-04-07 | 2014-03-13 | Susanne Weller | Verfahren zur Herstellung von rotierenden elektrischen Maschinen |
| DK3019619T3 (da) | 2013-07-11 | 2021-10-11 | Modernatx Inc | Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder |
| JP2015092462A (ja) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | 正極及びそれを用いたリチウムイオン二次電池 |
| DK3119797T3 (da) * | 2014-03-18 | 2021-03-15 | Univ Massachusetts | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose |
| WO2015141521A1 (ja) | 2014-03-21 | 2015-09-24 | 株式会社日立国際電気 | 基板処理装置、半導体装置の製造方法及び記録媒体 |
| US20170210788A1 (en) * | 2014-07-23 | 2017-07-27 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| JP6197169B2 (ja) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | 半導体装置の製造方法 |
-
2017
- 2017-03-31 JP JP2018551837A patent/JP7253379B2/ja active Active
- 2017-03-31 AU AU2017240236A patent/AU2017240236C1/en active Active
- 2017-03-31 RU RU2018137677A patent/RU2768289C2/ru active
- 2017-03-31 WO PCT/US2017/025614 patent/WO2017173411A1/en not_active Ceased
- 2017-03-31 CA CA3019832A patent/CA3019832C/en active Active
- 2017-03-31 IL IL262056A patent/IL262056B2/en unknown
- 2017-03-31 KR KR1020187031571A patent/KR102453187B1/ko active Active
- 2017-03-31 BR BR112018070249A patent/BR112018070249A2/pt not_active Application Discontinuation
- 2017-03-31 US US16/089,860 patent/US11345913B2/en active Active
- 2017-03-31 CN CN201780033090.6A patent/CN109714954A/zh active Pending
- 2017-03-31 EP EP23207092.0A patent/EP4335502A3/en active Pending
- 2017-03-31 MA MA044528A patent/MA44528A/fr unknown
- 2017-03-31 EP EP17776877.7A patent/EP3435755B1/en active Active
-
2022
- 2022-01-17 JP JP2022005011A patent/JP2022046792A/ja not_active Withdrawn
- 2022-04-26 US US17/729,751 patent/US11939579B2/en active Active
-
2024
- 2024-02-16 US US18/444,111 patent/US20250019697A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3435755B1 (en) | 2023-11-01 |
| JP2022046792A (ja) | 2022-03-23 |
| US11345913B2 (en) | 2022-05-31 |
| RU2768289C2 (ru) | 2022-03-23 |
| WO2017173411A1 (en) | 2017-10-05 |
| RU2018137677A3 (enExample) | 2020-07-23 |
| US20250019697A1 (en) | 2025-01-16 |
| EP3435755A1 (en) | 2019-02-06 |
| CA3019832A1 (en) | 2017-10-05 |
| US20190136235A1 (en) | 2019-05-09 |
| IL262056B2 (en) | 2023-10-01 |
| US11939579B2 (en) | 2024-03-26 |
| RU2018137677A (ru) | 2020-05-12 |
| JP2019515663A (ja) | 2019-06-13 |
| KR20180130550A (ko) | 2018-12-07 |
| AU2017240236A1 (en) | 2018-10-18 |
| NZ746893A (en) | 2025-05-30 |
| IL262056A (en) | 2018-11-29 |
| US20230077409A1 (en) | 2023-03-16 |
| JP7253379B2 (ja) | 2023-04-06 |
| CA3019832C (en) | 2023-05-09 |
| EP3435755A4 (en) | 2019-11-27 |
| EP4335502A3 (en) | 2024-07-03 |
| EP4335502A2 (en) | 2024-03-13 |
| CN109714954A (zh) | 2019-05-03 |
| AU2017240236B2 (en) | 2023-07-27 |
| AU2017240236C1 (en) | 2024-03-07 |
| IL262056B1 (en) | 2023-06-01 |
| MA44528A (fr) | 2019-02-06 |
| KR102453187B1 (ko) | 2022-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018070249A2 (pt) | sistema promotor de u6 modificada para expressão específica de tecido | |
| MX2017008500A (es) | Supresión del gen de la huntingtina inducida por la arni. | |
| AR121312A2 (es) | AGENTES DE ARNi, COMPOSICIONES Y MÉTODOS DE USO DE LOS MISMOS PARA TRATAR ENFERMEDADES ASOCIADAS CON TRANSTIRETINA (TTR) | |
| MX2018012880A (es) | Metodos para proporcionar arn de hebra sencilla. | |
| BR112017028318A2 (pt) | compostos antibacterianos | |
| EP4520841A3 (en) | Enzyme- and amplification-free sequencing | |
| BR112016003591A8 (pt) | promotor u6 de polimerase iii de soja e métodos de uso | |
| MX385048B (es) | Composiciones y metodos para inhibir la expresion del gen alas1. | |
| TR201818825T4 (tr) | Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar | |
| BR112016007226A2 (pt) | composições e métodos para inibição da expressão do gene alas1 | |
| BR112021023488A2 (pt) | Oligonucleotídeos de gapmer modificados e métodos de uso | |
| BR112015021210A2 (pt) | métodos e composições para o direcionamento de rna polimerases e biogênese de rna não codificante para locais específicos | |
| BR112016002524A2 (pt) | alvos moleculares para a prevenção e/ou tratamento de fibrose, cicatrizes hipertróficas e quelóides | |
| BR112018005940A2 (pt) | métodos de garantia da qualidade molecular para uso em sequenciamento | |
| MA39990A (fr) | Induction de régénération cardiaque par micro-arn | |
| MX381947B (es) | Mirna natural para controlar la expresion de gen y uso del mismo. | |
| BR112021006520A2 (pt) | ácido ribonucleico de fita dupla que inibe a expressão de c5 complementar | |
| MX2021013879A (es) | Variantes de lipasa y polinucleotidos que las codifican. | |
| BR112017012389A2 (pt) | supressão de rnai parental de gene kruppel para controlar pragas de coleóptero | |
| HK1223129A1 (zh) | 基因表现生物标记及其於潜在需要组蛋白去乙醯酶抑制剂治疗的患者的诊断和预後应用中的使用 | |
| PL403939A1 (pl) | Aptamery DNA rozpoznające metkę histydynową oraz ich zastosowanie | |
| UA114603C2 (uk) | Конструкція для сайленсингу гена p0 та її застосування | |
| MX380693B (es) | Produccion de manool. | |
| BR112017013970A2 (pt) | promotores específicos da semente de brassica napus identificados por análise de microarranjo | |
| AR090582A1 (es) | METODOS Y COMPOSICIONES PARA TRATAR CANCER USANDO ARNhc SRC 3 BIFUNCIONAL |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |